Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This study suggests that a biomaterial-based approach using microneedles and ion solutions to deliver SiO3 2− ions may disrupt inflammatory cycles and improve outcomes in inflammatory dilated cardiomyopathy (iDCM).

This study found that infrared thermography might be a useful non-invasive tool to help diagnose frontal fibrosing alopecia by identifying active phases of the disease.

In this study, researchers observed that P2X3-immunoreactive fibers extensively innervate the epidermis of rats, suggesting a primary role in detecting noxious stimuli in cutaneous tissue.

This study found that targeting both hormonal and immune pathways improved treatment outcomes in androgenetic alopecia patients with an under-recognized inflammatory component called PIILIF, which may contribute to treatment resistance.

In this 10-patient exploratory study, the researchers found that topical application of 4-aminopyridine 5% combined with microneedling did not improve hair density or quality in men with androgenetic alopecia, suggesting limited efficacy in this context despite promising results in animal wound models.

This study found that intralesional triamcinolone acetonide injections using a needleless injector led to rapid hair regrowth in patients with limited alopecia areata, while lasting growth was rare in alopecia totalis.

This snippet mentions an increase in women seeking surgical hair restoration and subsequently encountering more cases of frontal fibrosing alopecia, but the abstract doesn't contain results or conclusions.

In this case report, researchers observed that two sisters with congenital immune disorders experienced partial hair regrowth while receiving tofacitinib for severe alopecia areata, highlighting the need for careful clinical and laboratory monitoring due to potential infection risks associated with JAK inhibitor therapy.

This study found that transfollicular delivery using surfactant-based nanoparticles significantly enhanced antigen stability and immune response compared to other delivery methods, especially when combined with an adjuvant.

This study reported that dermatological adverse events are common in patients treated with amivantamab for non-small cell lung cancer, often impacting quality of life and requiring treatment modifications.

This study found that for thyroid cancer patients who underwent radical mastectomy, the combination of CAF regimen and fufangbanmao capsule improved short-term clinical efficacy, enhanced immune function, reduced drug toxicity, and positively impacted quality of life compared to the CAF regimen alone.

The researchers reported that human foreskin fibroblasts isolated by enzyme digestion method proliferated faster and were purified more quickly than those isolated by the inverted tissue culture method; additionally, post-psoralen photoactivation therapy moderately repaired UVB-induced damage in these fibroblasts, suggesting potential clinical applications.

This study found that topical liquid nitrogen improved pain tolerance during intradermal platelet-rich plasma therapy in androgenic alopecia compared to normal saline, although patient satisfaction did not significantly differ between groups.

In animal models, this study reported that a wound dressing combining quaternized chitin and silk fibroin significantly enhanced vascular reconstruction and hair follicle regeneration, approaching normal tissue levels.

This source reports that the JOLT technique using HA fillers is effective in lifting and tightening the lower face and neck, camouflaging the jowl, and improving marionette lines and the mandibular border.

This narrative review discusses the potential of urinary bladder matrix as a bio-scaffold in hair restoration but provides no new clinical results or trials; it highlights regenerative technology and suggests further exploration.

In this study, researchers developed a hierarchically engineered microreactor that effectively combats infected wounds by releasing antimicrobials at acidic sites, eradicating MRSA while avoiding resistance, and enhancing tissue repair through immune system modulation.

No results are provided in this article as it lacks an available abstract, making it unclear what effects apremilast and tofacitinib have in a humanized mouse model of alopecia areata.

This study observed complete resolution of neuropathic pain symptoms in a patient after a fat grafting PRP procedure, suggesting it may be a less invasive treatment alternative.

This study found that plasma rich in growth factors (PRGF) as an adjuvant to follicular unit extraction (FUE) surgery may enhance hair graft performance and reduce post-surgical inflammation and pain in hair loss patients.

This study of alopecia areata patients found that a 10 mg twice-daily dose of oral tofacitinib led to significant hair regrowth, suggesting it may be beneficial for treatment.

This study found that prolonged tofacitinib treatment in adult Indian patients with moderate-to-severe alopecia areata was associated with a high regrowth rate, which varied with factors like age at disease onset and treatment duration.

This study developed BroadAMP-GPT, a computational-experimental framework, to discover new antimicrobial peptides, identifying candidates effective against multidrug-resistant pathogens. Notably, AMP_S13 showed strong stability, low toxicity, and efficacy in infection models, highlighting the platform's potential in combating antimicrobial resistance.

This letter discusses the use of UVA-1 in the treatment of alopecia areata but reports no new clinical results.

In this study, the SAFE System for follicular unit extraction demonstrated a favorable average follicle transection rate of 6.14% and is accessible for physicians with basic technical skills, showing promise for wider adoption.

This abstract contains author information and a disclosure regarding the Mohebi Inserter for hair transplantation but provides no new clinical research findings.